gastrojournal.org
/6 days ago
Targeting oncomucin-driven immunosuppression improves the efficacy of K-rasG12D inhibition in pancreatic cancer
Oncogenic de novo mucins (oncoMUCs; MUC4, MUC16, and MUC5AC) are progressively upregulated in pancreatic ductal adenocarcinoma (PDA). While their individual cell-intrinsic roles ha...